Journal article
HSF1 is a driver of leukemia stem cell self-renewal in acute myeloid leukemia
Nature communications, Vol.13(1), pp.6107-6107
10/16/2022
DOI: 10.1038/s41467-022-33861-1
PMCID: PMC9573868
PMID: 36245043
Abstract
Acute myeloid leukemia (AML) is maintained by self-renewing leukemic stem cells (LSCs). A fundamental problem in treating AML is that conventional therapy fails to eliminate LSCs, which can reinitiate leukemia. Heat shock transcription factor 1 (HSF1), a central regulator of the stress response, has emerged as an important target in cancer therapy. Using genetic Hsf1 deletion and a direct HSF1 small molecule inhibitor, we show that HSF1 is specifically required for the maintenance of AML, while sparing steady-state and stressed hematopoiesis. Mechanistically, deletion of Hsf1 dysregulates multifaceted genes involved in LSC stemness and suppresses mitochondrial oxidative phosphorylation through downregulation of succinate dehydrogenase C (SDHC), a direct HSF1 target. Forced expression of SDHC largely restores the Hsf1 ablation-induced AML developmental defect. Importantly, the growth and engraftment of human AML cells are suppressed by HSF1 inhibition. Our data provide a rationale for developing efficacious small molecules to specifically target HSF1 in AML.
Details
- Title: Subtitle
- HSF1 is a driver of leukemia stem cell self-renewal in acute myeloid leukemia
- Creators
- Qianze Dong - Case Western Reserve UniversityYan Xiu - Department of Pathology, Louis Stokes Veterans Affairs Medical Center, Cleveland, OH, 44106, USAYang Wang - Case Western Reserve UniversityChristina Hodgson - MAWD Pathology Group, Kansas City, MO, 66215, USANick Borcherding - Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, 63110, USACraig Jordan - Division of Hematology, University of Colorado Anschutz Campus, Denver, CO, 80045, USAJane Buchanan - Department of Biochemistry, Carver College of Medicine, University of Iowa, Iowa City, IA, 52240, USAEric Taylor - Department of Biochemistry, Carver College of Medicine, University of Iowa, Iowa City, IA, 52240, USABrett Wagner - University of IowaMariah Leidinger - Department of Pathology, University of Iowa, Iowa City, IA, 52242, USACarol Holman - Department of Pathology, University of Iowa, Iowa City, IA, 52242, USADennis J Thiele - Sisu Pharma, Inc., Chapel Hill, NC, 27514, USASean O'Brien - Sisu Pharma, Inc., Chapel Hill, NC, 27514, USAHai-Hui Xue - Hackensack University Medical CenterJinming Zhao - Department of Pathology, China Medical University, 77 Puhe Rd, Shenbei Xinqu, Shenyang Shi, 110122, Liaoning Sheng, ChinaQingchang Li - Department of Pathology, China Medical University, 77 Puhe Rd, Shenbei Xinqu, Shenyang Shi, 110122, Liaoning Sheng, ChinaHoward Meyerson - University Hospitals of ClevelandBrendan F Boyce - University of Rochester Medical CenterChen Zhao - University Hospitals of Cleveland
- Resource Type
- Journal article
- Publication Details
- Nature communications, Vol.13(1), pp.6107-6107
- DOI
- 10.1038/s41467-022-33861-1
- PMID
- 36245043
- PMCID
- PMC9573868
- NLM abbreviation
- Nat Commun
- ISSN
- 2041-1723
- eISSN
- 2041-1723
- Grant note
- F30 DK127845 / NIDDK NIH HHS R01 CA237006 / NCI NIH HHS R01 DK104998 / NIDDK NIH HHS P30 CA086862 / NCI NIH HHS
- Language
- English
- Date published
- 10/16/2022
- Academic Unit
- Dermatology; Molecular Physiology and Biophysics; Pathology; Radiation Oncology; Fraternal Order of Eagles Diabetes Research Center
- Record Identifier
- 9984383903402771
Metrics
17 Record Views